SK8096A3 - 2,9-disubstituted purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use - Google Patents

2,9-disubstituted purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use Download PDF

Info

Publication number
SK8096A3
SK8096A3 SK80-96A SK8096A SK8096A3 SK 8096 A3 SK8096 A3 SK 8096A3 SK 8096 A SK8096 A SK 8096A SK 8096 A3 SK8096 A3 SK 8096A3
Authority
SK
Slovakia
Prior art keywords
carbon atoms
straight
branched alkyl
group
substituted
Prior art date
Application number
SK80-96A
Other languages
English (en)
Slovak (sk)
Inventor
Ulrich Niewohner
Erwin Bischoff
Helmuth Schutz
Elisabeth Perzborn
Matthias Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SK8096A3 publication Critical patent/SK8096A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK80-96A 1995-01-19 1996-01-18 2,9-disubstituted purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use SK8096A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501482A DE19501482A1 (de) 1995-01-19 1995-01-19 2,9-disubstituierte Purin-6-one

Publications (1)

Publication Number Publication Date
SK8096A3 true SK8096A3 (en) 1996-08-07

Family

ID=7751830

Family Applications (1)

Application Number Title Priority Date Filing Date
SK80-96A SK8096A3 (en) 1995-01-19 1996-01-18 2,9-disubstituted purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use

Country Status (31)

Country Link
US (1) US5861404A (fr)
EP (1) EP0722944A1 (fr)
JP (1) JPH08231545A (fr)
KR (1) KR960029334A (fr)
CN (1) CN1135485A (fr)
AR (1) AR002953A1 (fr)
AU (1) AU4097996A (fr)
BG (1) BG61728B1 (fr)
BR (1) BR9600147A (fr)
CA (1) CA2167353A1 (fr)
CO (1) CO4700523A1 (fr)
CZ (1) CZ16696A3 (fr)
DE (1) DE19501482A1 (fr)
EE (1) EE9600018A (fr)
FI (1) FI960225L (fr)
HR (1) HRP960007A2 (fr)
HU (1) HUP9600106A3 (fr)
IL (1) IL116769A (fr)
MA (1) MA23778A1 (fr)
NO (1) NO960223L (fr)
NZ (1) NZ280830A (fr)
PE (1) PE64996A1 (fr)
PL (1) PL312354A1 (fr)
SG (1) SG50401A1 (fr)
SK (1) SK8096A3 (fr)
SV (1) SV1996000006A (fr)
TN (2) TNSN96006A1 (fr)
TR (1) TR199600028A2 (fr)
TW (1) TW314519B (fr)
YU (1) YU1396A (fr)
ZA (1) ZA96398B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529102A1 (de) * 1995-08-08 1997-02-13 Kummer Horst Dieter Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
NZ502752A (en) * 1997-07-15 2001-01-26 Japan Energy Corp Purine derivatives and their use in the treatment of nephritis
CN1130363C (zh) * 1997-11-12 2003-12-10 三菱化学株式会社 嘌呤衍生物以及含有其作为有效成分的药物
AU1688599A (en) * 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
WO2000068231A1 (fr) * 1999-05-11 2000-11-16 Mitsubishi Chemical Corporation Dihydrate derive de purine, medicaments le contenant comme principe actif et intermediaire utilise dans sa preparation
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
CN1264574C (zh) * 2000-09-06 2006-07-19 田边制药株式会社 口服制剂
NZ527585A (en) * 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CN102742513A (zh) * 2012-07-17 2012-10-24 南京熊猫机电制造有限公司 一种喂食栏装置
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
MA55556A (fr) 2019-04-02 2022-02-09 Aligos Therapeutics Inc Composés ciblant prmt5
JP7385467B2 (ja) * 2019-12-26 2023-11-22 キッセイ薬品工業株式会社 ヒポキサンチン化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
BG100292A (bg) 1996-07-31
SG50401A1 (en) 1998-07-20
HUP9600106A3 (en) 1998-04-28
DE19501482A1 (de) 1996-07-25
AR002953A1 (es) 1998-05-27
TNSN96006A1 (fr) 2005-03-15
SV1996000006A (es) 1996-10-29
BR9600147A (pt) 1998-01-06
CA2167353A1 (fr) 1996-07-20
TNSN96007A1 (fr) 2005-03-15
PL312354A1 (en) 1996-07-22
TR199600028A2 (tr) 1996-08-21
HU9600106D0 (en) 1996-03-28
NO960223D0 (no) 1996-01-18
PE64996A1 (es) 1997-03-09
CO4700523A1 (es) 1998-12-29
FI960225A0 (fi) 1996-01-17
FI960225A7 (fi) 1996-07-20
IL116769A0 (en) 1996-05-14
AU4097996A (en) 1996-07-25
TW314519B (fr) 1997-09-01
MA23778A1 (fr) 1996-10-01
EE9600018A (et) 1996-08-15
ZA96398B (en) 1996-08-28
CN1135485A (zh) 1996-11-13
EP0722944A1 (fr) 1996-07-24
CZ16696A3 (en) 1996-08-14
YU1396A (sh) 1999-03-04
HRP960007A2 (en) 1998-02-28
US5861404A (en) 1999-01-19
BG61728B1 (bg) 1998-04-30
NO960223L (no) 1996-07-22
HUP9600106A2 (en) 1997-05-28
NZ280830A (en) 1998-04-27
IL116769A (en) 1998-12-06
FI960225L (fi) 1996-07-20
KR960029334A (ko) 1996-08-17
JPH08231545A (ja) 1996-09-10

Similar Documents

Publication Publication Date Title
SK8096A3 (en) 2,9-disubstituted purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use
SK7796A3 (en) 2,8-disubstituted quinazolines, their manufacturing process, pharmaceutical drug containing these substances and their application
US6794391B2 (en) Derivatives of pyrimido[6.1-a]isoquinolin-4-one
AU720305B2 (en) Purin-6-one derivatives
EP0370901B1 (fr) Nouveaux dérivés du chromanne actifs sur le système nerveux central, leur procédé de préparation et les compositions pharmaceutiques en contenant
SK7696A3 (en) 9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use
US5721267A (en) Chemotherapeutic pyrrolocarbazole derivatives
EP0586585B1 (fr) 1,2-dihydropyrido (3,4-b)pyrazines utilisees comme fongicides
WO1992012979A1 (fr) ACIDES ACETIQUES 2,4-DIOXO-PYRIDO [2,3-d] PYRIMIDINE-3- AINSI QUE LEURS ESTERS ET LEURS SELS
DE102004060752A1 (de) Hetaryloxy-substituierte Phenylaminopyrimidine